When was BeiGene founded?

BeiGene was founded in 2010 and raised its 1st funding round 1 year after it was founded.

Where is BeiGene located?

BeiGene is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts.

Who is the current CEO of BeiGene?

John V Oyler of BeiGene. They have also founded 1 company.

How many employees does BeiGene have?

As of Jun 30, 2026, the latest employee count at BeiGene is 1960.

Is BeiGene a funded company?

BeiGene is a funded company, having raised a total of $172M across 6 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on May 02, 2011.

When was the latest funding round of BeiGene?

BeiGene's latest funding was a $***** Post IPO round on Jul 15, 2020, with participation from 1 investor.

What is the annual revenue of BeiGene?

Annual revenue of BeiGene is more than $1B as on Dec 31, 2024

Where does BeiGene rank among its competitors?

BeiGene ranks 15th amongst 3619 active competitors, of which 1236 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Senti Bio, which secured $40M in May, 2026.

Who are the top competitors of BeiGene?

BeiGene's top competitors include Jazz Pharmaceuticals, Biogen and Abcellera Biologics. Among them, Senti Bio secured the most recent funding round in May, 2026.

BeiGene - 2026 Company Profile, Team, Funding, Competitors & Financials

BeiGene is a public company based in Cambridge (United States), founded in 2010 by John V Oyler. It operates as a Developer of targeted and immune-oncology drugs against cancer. BeiGene has raised $172M in funding from Hillhouse. The company has 3619 active competitors, including 1236 funded and 862 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Biogen and Abcellera Biologics.

Company Details

Developer of targeted and immune-oncology drugs against cancer. The company's product pipeline includes oral small molecule inhibitors and monoclonal antibodies, such as BGB-3111, an oral inhibitor of Bruton tyrosine kinase, BGB-283, a B-RAF inhibitor; and BGB-290, a poly (ADP-ribose) polymerase inhibitor. Also, has another candidate BGB-108, a potentially differentiated PD-1 monoclonal antibody candidate.

Website: beigene.com
Email ID: *****@beigene.com
Phone Number: +1 **********
Registered Address: Cambridge, Massachusetts

Key Metrics

Founded Year

2010

Location

Cambridge, United States

Stage

Public

Total Funding

$172M in 6 rounds

Latest Funding Round

Post IPO, Jul 15, 2020, $*****

Investors

Hillhouse & 14 more

Ranked

15^th among 3619 active competitors

Annual Revenue

$1B+ as on Dec 31, 2024

Employee Count

1,960 as on Jun 30, 2026

Investment & Acquisitions

Shixi Biology & 5 more

Similar Companies

Biogen & 1135 more

Exit Details

Public

View BeiGene's full profile

BeiGene is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
BEIGENE USA, INC. CIN: 364815718 , United States, Active	Dec 26, 999	-	1650 (As on Dec 31, 2024)	-
Beigene, Ltd. CIN: 1651308 , United States, Active	Aug 27, 2015	$1B+ (As on Dec 31, 2024)	-	-
BEIGENE, LTD CIN: 98-1209416 , United States, Active	Dec 31, 2009	-	10600 (As on Feb 29, 2024)	-

BeiGene got listed on Feb 03, 2016.

Click here to take a look at BeiGene's IPO in detail

BeiGene has raised a total funding of $172M over 6 rounds. Its first funding round was on May 02, 2011. Its latest funding round was a Post IPO round on Jul 15, 2020 for $*****. 1 investor participated in its latest round. BeiGene has 15 institutional investors.

Here is the list of recent funding rounds of BeiGene:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 15, 2020	5095379	Post IPO	3819705	4340074	6540825	2091622
Oct 31, 2019	6052762	Post IPO	8596039	8389832	8990430	Amgen
May 13, 2015	1818716	Series B	2661176	5433481	Hillhouse	Rock Springs Capital & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of BeiGene's funding rounds and investors

The founders of BeiGene is John V Oyler. John V Oyler is the CEO of BeiGene.

Here are the details of BeiGene's key team members:

John V Oyler: Founder & CEO of BeiGene and founder of 1 other company.

View details of BeiGene's Founder profiles and Board Members

BeiGene's employee count trend

BeiGene has 1,960 employees as of Jun 26. Here is BeiGene's employee count trend over the years:

Uncover BeiGene's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of BeiGene include Jazz Pharmaceuticals, Biogen and Abcellera Biologics. Here is the list of Top 10 competitors of BeiGene, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	76/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
5th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Omnes Capital, Life Sciences Partners & 20 others	74/100
6th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
7th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, SV Health Investors & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
10th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
15th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Boxer Capital, Fidelity Investments & 13 others	80/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on BeiGene's competitors? Click here to see the top ones

BeiGene has not made any acquisitions yet. BeiGene has made 6 investments.

Here is the list of latest three $investments:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Jun 28, 2024	Investments	Shixi Biology	2021	Huangpu (China)
Jan 31, 2023	Investments	Duo Oncology	2020	Pittsburgh (United States)
Nov 02, 2021	Investments	Shoreline Biosciences	2020	San Diego (United States)